ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY

Purpose: To evaluate the role of antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity (ROP). Methods: In this noncomparative, prospective, interventional case series, bevacizumab was injected into the vitreous of patients with ROP in three different groups: group I, patients with stage IVa or IVb ROP who had no response to conventional treatment; group II, patients with threshold ROP who were difficult to treat with conventional therapy because of poor visualization of the retina; and group III, patients with high-risk prethreshold or threshold ROP. Results: Thirteen patients (18 eyes; mean age ± SD, 4 ± 3 months; mean follow-up, 6 months) were included in the study. We found neovascular regression in 17 eyes. One patient with stage IVa ROP had spontaneous retinal reattachment after an intravitreal injection of bevacizumab. There were no serious ocular or systemic adverse events. Conclusion: The use of bevacizumab may be promising in the treatment of patients with ROP. Further studies need to be performed to determine the safety and long-term efficacy of intravitreal injection of bevacizumab, either as first-line therapy or after failure of conventional therapy.

[1]  H. Quiroz-Mercado,et al.  Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  T. Hirose,et al.  An International Classification of Retinopathy of Prematurity: II. The Classification of Retinal Detachment , 1987 .

[3]  W. Tasman,et al.  Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. , 2002, Archives of ophthalmology.

[4]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[5]  A. Patz.  An International Classification of Retinopathy of Prematurity: II. The Classification of Retinal Detachment , 1987 .

[6]  A. Fielder,et al.  Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. , 2003, Archives of ophthalmology.

[7]  A. Madan.  Angiogenesis and Antiangiogenesis in the Neonate: Relevance to Retinopathy of Prematurity , 2003 .

[8]  R. Newsom,et al.  UK retinopathy of prematurity treatment survey , 2007, Eye.

[9]  J. Stone,et al.  Structure of the macroglia of the retina: Sharing and division of labour between astrocytes and Müller cells , 1991, The Journal of comparative neurology.

[10]  M. Martinez-Castellanos,et al.  Our Experience After 1765 Intravitreal Injections of Bevacizumab: The Importance of Being Part of a Developing Story , 2007, Seminars in ophthalmology.

[11]  Lois E. H. Smith,et al.  Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. , 1996, Archives of ophthalmology.

[12]  S. Harper,et al.  VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. , 2006, Molecular vision.

[13]  L. Aiello,et al.  EVOLVING GUIDELINES FOR INTRAVITREOUS INJECTIONS , 2004, Retina.

[14]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[15]  J. Penn,et al.  Variable oxygen exposure causes preretinal neovascularization in the newborn rat. , 1993, Investigative ophthalmology & visual science.

[16]  M. Repka,et al.  Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). , 2006, Archives of ophthalmology.

[17]  W. Tasman,et al.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. , 2004, Archives of ophthalmology.

[18]  M. Trese.  Two-hand dissection technique during closed vitrectomy for retinopathy of prematurity. , 1986, American journal of ophthalmology.

[19]  J. Stone,et al.  Chapter 7 Retinopathy of prematurity: Origins in the architecture of the retina , 1993 .

[20]  J. Stone,et al.  Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. , 1996, Investigative ophthalmology & visual science.

[21]  Allen Foster,et al.  Retinopathy of prematurity in middle-income countries , 1997, The Lancet.

[22]  R. Wright,et al.  THE IMPORTANCE OF RADIOGRAPHY IN DOUBTFUL CASES OF OPTIC ATROPHY WITH SPECIAL REFERENCE TO PITUITARY DISEASE , 1923, The British journal of ophthalmology.

[23]  Isaac Ben-Sira,et al.  An international classification of retinopathy of prematurity. Clinical experience. , 1985, Ophthalmology.

[24]  J. Stone,et al.  Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  Lois E. H. Smith,et al.  Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Chan-Ling,et al.  Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. , 2000, Investigative ophthalmology & visual science.

[27]  A. Filouš,et al.  [Retinopathy of prematurity]. , 1998, Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti.

[28]  M. Goldberg.  Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. , 1997, American journal of ophthalmology.

[29]  Karen W. Miller,et al.  Incidence and Early Course of Retlnonathy of Prematurity , 1991 .

[30]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Hirose,et al.  Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. , 2000, The American journal of pathology.

[32]  K. Hutcheson.  Retinopathy of prematurity , 2003, Current opinion in ophthalmology.

[33]  J. Rivera,et al.  Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. , 2004, Investigative ophthalmology & visual science.

[34]  Sander R. Dubovy,et al.  SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[35]  E. Becerril,et al.  Growth Factor Levels and ROP , 2005 .

[36]  A. Fielder,et al.  Natural history of retinopathy of prematurity: A prospective study , 1992, Eye.

[37]  J. M. Gallardo Galera,et al.  Growth factor levels and ROP. , 2005, Ophthalmology.

[38]  V. Rajaratnam,et al.  Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. , 1998, Growth factors.

[39]  D. Charteris,et al.  Late onset vitreoretinal complications of regressed retinopathy of prematurity , 2004, British Journal of Ophthalmology.